Allied Market Research

2024

Megalencephaly-polymicrogyria-polydactyly-hydrocephalus Syndrome Market

Megalencephaly-polymicrogyria-polydactyly-hydrocephalus Syndrome Market Size, Share, Competitive Landscape and Trend Analysis Report by Symptoms, by Treatment, by End-Users and by DISTRIBUTION CHANNEL : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome is a rare disorder that affects the brain development. Affected individuals are born with megalencephaly (a large brain and head size). The brain and head continue to grow quite rapidly in the first two years of the patient’s life. In addition, the MPPH syndrome is associated with bilateral perisylvian polymicrogyria, which is a brain abnormality. The surface of the brain has many folds and ridges, called gyri. The problems with brain development cause a variety of neurological signs and symptoms. Individuals suffering from this syndrome have an intellectual disability and delayed development of the body. Moreover, they face difficulty in coordinating the mouth movements and tongue (known as oromotor dysfunction).

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industry industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market.

Top Impacting Factors

Rise in multiple birth defect cases that cause MPPH syndrome and surge in prevalence of developmental delay across the globe are the major factors that drive the growth of the global megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market.

Moreover, alarming increase in incidence of nerve disorders among infants and surge in the cases of gene expression changes that occur due to chemical modification in the fetus’ DNA accelerate the growth of the market. Furthermore, upsurge in R&D activities by biotechnology and pharmaceutical companies with the purpose of improving the treatment for MPPH syndrome further influence the market.

In addition, increase in awareness regarding MPPH, developing healthcare infrastructure, rise in funds for R&D, and surge in healthcare expenditure positively affect the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market.

However, the population is less open to therapies that target treatment in infants from the embryonic stage, which hamper the growth of the market growth during the forecast period. High cost associated with the treatment of this syndrome further hamper the market growth during the study period.

Market Trends

Many pharmaceutical companies such as Ionis Pharmaceuticals and Novo Nordisk A/S are now delivering low-cost personalized products to patients on account of emerging developments in the healthcare sector, leading to rising customer expectations.

Various companies are focusing on organic growth strategies, which include product approvals, product launches, and others such as events and patents. Inorganic growth strategies that are witnessed in the market include partnership & collaborations and acquisitions.

The key market players for the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome are focusing on portals that are dedicated to rare diseases and orphan drugs. Orphan drugs are rare drugs for rare disorders. These drugs are not profitable to produce without financial assistance from the government or other external sources.

Key Benefits of the Report

  • This study presents the analytical depiction of the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in the coming years

Questions Answered in the Global megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome Market Report

  • Which are the leading players active in the megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market?
  • How is each segment of the market expected to grow ?
  • What are the adoption trends for megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome?
  • What is megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome market prediction in the future?
  • What are the current trends and predicted trends?

Megalencephaly-polymicrogyria-polydactyly-hydrocephalus Syndrome Market Report Highlights

Aspects Details
icon_5
By Symptoms
  • Polymicrogyria
  • Megalencephaly
  • Intellectual Disability
  • Seizures
  • Polydactyly
  • Hydrocephalus
icon_6
By Treatment
  • Neurosurgery
  • Genetic Therapy
  • Drugs
  • Others
icon_7
By End-Users
  • Hospitals and Clinics
  • Surgical Centers
  • Diagnostic Centers
  • Others
icon_8
By DISTRIBUTION CHANNEL
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
icon_9
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_10
Key Market Players

Ionis Pharmaceuticals, Takeda Pharmaceutical Company Limited.,, CYTOKINETICS, INC., Regeneron Pharmaceuticals Inc., Pfizer Inc., Boehringer Ingelheim International GmbH., Novartis AG, Salarius Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Natera, Leadiant Biosciences, Inc., Abbott, PTC Therapeutics., Catalyst Pharmaceuticals, Inc., Novo Nordisk A/S

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Megalencephaly-polymicrogyria-polydactyly-hydrocephalus Syndrome Market

Global Opportunity Analysis and Industry Forecast, 2023-2032